International Journal of Oral Biology

The Korean Academy of Oral Biology (대한구강생물학회)
권호 표지
DOI QR코드

DOI QR Code

A Neuromedin B Receptor Blockade Inhibits the Growth of Human Oral Cancer Cells

  • Park, Hyun-Joo (Department of Oral Physiology, School of Dentistry, Pusan National University) ;
  • Jeon, Jae-Hoon (Department of Oral Physiology, School of Dentistry, Pusan National University) ;
  • Kim, Mi-Kyoung (Department of Oral Physiology, School of Dentistry, Pusan National University) ;
  • Ryu, Mi Heon (Department of Oral Pathology, School of Dentistry, Pusan National University) ;
  • Kim, Yong-Deok (Department of Oral and Maxillofacial Surgery, School of Dentistry, Pusan National University) ;
  • Bae, Soo-Kyung (Department of Dental Pharmacology, School of Dentistry, Pusan National University) ;
  • Bae, Moon-Kyoung (Department of Oral Physiology, School of Dentistry, Pusan National University)
  • Received : 2014.01.02
  • Accepted : 2014.01.26
  • Published : 2014.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Neuromedin B (NMB) acts as a growth factor or a morphogen and plays a role in cancer progression. Indeed, the NMB receptor (NMB-R) is overexpressed in different types of tumors. In our current study, we investigated the involvement of NMB-R in the proliferation of oral cancer cells. Human oral squamous cell carcinoma (SCC) and human oral cancer cells, SCC-25 cells were found to be NMB-R-positive. The NMB-R antagonist PD168368 inhibited the proliferation of SCC-25 cells and reduced their colony formation capacity. We also found that PD168368 induced the cell cycle arrest and apoptosis of SCC-25 cells in a dose-/time-dependent manner. Overall, this antitumor activity of PD168368 in human oral cancer cells suggests that NMB-R is a potential target for the future prevention and treatment of human cancers.

Keywords

References

  1. Gonzalez N, Moody TW, Igarashi H, Ito T, Jensen RT. Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states. Curr Opin Endocrinol Diabetes Obes. 2008;15:58-64. https://doi.org/10.1097/MED.0b013e3282f3709b
  2. Ohki-Hamazaki H, Iwabuchi M, Maekawa F. Development and function of bombesin-like peptides and their receptors. Int J Dev Biol. 2005;49:293-300. https://doi.org/10.1387/ijdb.041954ho
  3. Patel O, Shulkes A, Baldwin GS. Gastrin-releasing peptide and cancer. Biochim Biophys Acta. 2006;1766:23-41.
  4. Preston SR, Miller GV, Primrose JN. Bombesin-like peptides and cancer. Crit Rev Oncol Hematol. 1996; 23:225-238. https://doi.org/10.1016/1040-8428(96)00204-1
  5. Park HJ, Kim SR, Bae SK, Choi YK, Bae YH, Kim EC, Kim WJ, Jang HO, Yun I, Kim YM, Bae MK. Neuromedin B induces angiogenesis via activation of ERK and Akt in endothelial cells. Exp Cell Res. 2009;315:3359-3369. https://doi.org/10.1016/j.yexcr.2009.08.009
  6. Martinez A, Zudaire E, Julian M, Moody TW, Cuttitta F. Gastrin-releasing peptide (GRP) induces angiogenesis and the specific GRP blocker 77427 inhibits tumor growth in vitro and in vivo. Oncogene 2005;24:4106-4113. https://doi.org/10.1038/sj.onc.1208581
  7. Zhou J, Chen J, Mokotoff M, Ball ED. Targeting gastrin-releasing peptide receptors for cancer treatment. Anticancer Drugs 2004;15:921-927. https://doi.org/10.1097/00001813-200411000-00001
  8. Qiao J, Kang J, Ishola TA, Rychahou PG, Evers BM, Chung DH. Gastrin-releasing peptide receptor silencing suppresses the tumorigenesis and metastatic potential of neuroblastoma. Proc Natl Acad Sci USA. 2008;105: 12891-12896. https://doi.org/10.1073/pnas.0711861105
  9. Hohla F, Schally AV, Kanashiro CA, Buchholz S, Baker B, Kannadka C, Moder A, Aigner E, Datz C, Halmos G. Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras,COX-2, and pAkt. Proc Natl Acad Sci USA. 2007;104:18671-18676. https://doi.org/10.1073/pnas.0709455104
  10. Park HJ, Kim SR, Kim MK, Choi KS, Jang HO, Yun I, Bae SK, Bae MK. Neuromedin B receptor antagonist suppresses tumor angiogenesis and tumor growth in vitro and in vivo. Cancer Lett. 2011;312:117-127. https://doi.org/10.1016/j.canlet.2011.08.014
  11. da Silva SD, Ferlito A, Takes RP, Brakenhoff RH, Valentin MD, Woolgar JA, Bradford CR, Rodrigo JP, Rinaldo A, Hier MP, Kowalski LP. Advances and applications of oral cancer basic research. Oral Oncol. 2011;47:783-791. https://doi.org/10.1016/j.oraloncology.2011.07.004
  12. Brinkman BM, Wong DT. Disease mechanism and biomarkers of oral squamous cell carcinoma. Curr Opin Oncol. 2006;18:228-233. https://doi.org/10.1097/01.cco.0000219250.15041.f8
  13. Shin WC, Kim CS, Kim HJ, Lee MH, Kim HR, Kim DK. Growth inhibition of human head and neck squamous cell carcinomas by Angelica decursiva extracts. Int J Oral Biol. 2010;35:153-158.
  14. Jang NM, Oh SH, Kim IR, Park HR, Park BS. The role of HS-1200 induced autophagy in oral cancer cells. Int J Oral Biol. 2013;38:93-100. https://doi.org/10.11620/IJOB.2013.38.3.093
  15. Lizard G, Miguet C, Gueldry S, Monier S, Gambert P. Flow cytometry measurement of DNA fragmentation in the course of cell death via apoptosis. New techniques for evaluation of DNA status for the pathologist. Ann Pathol. 1997;17:61-66.
  16. Rozengurt E. Neuropeptides as growth factors for normal and cancerous cells. Trends Endocrinol Metab. 2002; 13:128-134. https://doi.org/10.1016/S1043-2760(01)00544-6
  17. Heasley LE. Autocrine and paracrine signaling through neuropeptide receptors in human cancer. Oncogene 2001;20:1563-1569. https://doi.org/10.1038/sj.onc.1204183
  18. Jensen RT, Battey JF, Spindel ER, Benya RV. International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev. 2008;60:1-42. https://doi.org/10.1124/pr.107.07108
  19. Cardona C, Rabbitts PH, Spindel ER, Ghatei MA, Bleehen NM, Bloom SR, Reeve JG. Production of neuromedin B and neuromedin B gene expression in human lung tumor cell lines. Cancer Res. 1991;51:5205-5211.
  20. Jensen JA, Carroll RE, Benya RV. The case for gastrinreleasing peptide acting as a morphogen when it and its receptor are aberrantly expressed in cancer. Peptides 2001;22:689-699. https://doi.org/10.1016/S0196-9781(01)00380-1
  21. Matusiak D, Glover S, Nathaniel R, Matkowskyj K, Yang J, Benya RV. Neuromedin B and its receptor are mitogens in both normal and malignant epithelial cells lining the colon. Am J Physiol Gastrointest Liver Physiol. 2005;288:G718-728. https://doi.org/10.1152/ajpgi.00156.2004
  22. Egloff AM, Liu X, Davis AL, Trevelline BK, Vuga M, Siegfried JM, Grandis JR. Elevated gastrin-releasing peptide receptor mRNA expression in buccal mucosa: association with head and neck squamous cell carcinoma. Head Neck 2013;35:270-279. https://doi.org/10.1002/hed.22963
  23. Lango MN, Dyer KF, Lui VW, Gooding WE, Gubish C, Siegfried JM, Grandis JR. Gastrin-releasing peptide receptor-mediated autocrine growth in squamous cell carcinoma of the head and neck. J Natl Cancer Inst. 2002;94:375-383. https://doi.org/10.1093/jnci/94.5.375
  24. Majumdar ID, Weber HC. Biology of mammalian bombesin-like peptides and their receptors. Curr Opin Endocrinol Diabetes Obes. 2011;18:68-74. https://doi.org/10.1097/MED.0b013e328340ff93
  25. Ohki-Hamazaki H. Neuromedin B. Prog Neurobiol. 2000;62:297-312. https://doi.org/10.1016/S0301-0082(00)00004-6
  26. Park HJ, Kim MK, Kim SR, Bae SK, Bae MK. Hypoxia Regulates the Expression of the Neuromedin B Receptor through a Mechanism Dependent on Hypoxia-Inducible Factor-$1\alpha$. PLoS One 2013;8:e82868. https://doi.org/10.1371/journal.pone.0082868
  27. Moody TW, Berna MJ, Mantey S, Sancho V, Ridnour L, Wink DA, Chan D, Giaccone G, Jensen RT. Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells. Eur J Pharmacol. 2010;637:38-45. https://doi.org/10.1016/j.ejphar.2010.03.057
  28. Cornelio DB, Roesler R, Schwartsmann G. Gastrin- releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann Oncol. 2007;18:1457-1466. https://doi.org/10.1093/annonc/mdm058
  29. Moody TW, Jensen RT, Garcia L, Leyton J. Nonpeptide neuromedin B receptor antagonists inhibit the proliferation of C6 cells. Eur J Pharmacol. 2000;409:133-142. https://doi.org/10.1016/S0014-2999(00)00828-1